Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine

Developmental Brain Research

Volumn 111, Issue 1, 1998, Pages 35-42

  Belcheva, Mariana M ^a   Bohn, Laura M ^a   Ho, Matthew T ^a   Johnson, Frank E ^a   Yanai, Joseph ^b   Barron, Susan ^c   Coscia, Carmine J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Buprenorphine; Cross linking; Down regulation; mRNA expression; Opioid receptor; Up regulation

Indexed keywords

BETA ENDORPHIN; BUPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; FEMALE; MALE; NEWBORN; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANIMALS, NEWBORN; BETA-ENDORPHIN; BRAIN; BUPRENORPHINE; CROSS-LINKING REAGENTS; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALINS; FEMALE; NARCOTIC ANTAGONISTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0032212069     PISSN: 01653806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-3806(98)00117-5     Document Type: Article

References (44)

1. Barron S., Chung V.M. Prenatal buprenorphine exposure and sexually dimorphic nonreproductive behaviors in rats. Pharmacol. Biochem. Behav. 58:1997;337-343.
2. Belcheva M.M., Ho M.T., Ignatova E., Jefcoat L.B., Barg J., Vogel Z., McHale R.J., Johnson F.E., Coscia C.J. Buprenorphine differentially alters opioid receptor adaptation in rat brain regions. J. Pharmacol. Exp. Ther. 277:1996;1322-1327.
3. 125I-β-endorphin cross-linked products in subcellular fractions from NG108-15 cells Biochemistry. 35:1996;14818-14824.
4. Belcheva M.M., Dawn S., Barg J., McHale R., Ho M., Ignatova E., Coscia C.J. Transient down-regulation of neonatal rat brain μ-opioid receptors upon in utero exposure to buprenorphine. Dev. Brain Res. 80:1994;158-162.
5. Belcheva M.M., Barg J., McHale R.J., Dawn S., Ho M., Ignatova E., Coscia C.J. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol. Pharmacol. 44:1993;173-179.
6. Belcheva M., Barg J., McHale R.J., Gao X.-M., Chuang D.-M., Coscia C.J. Up-regulation of δ opioid receptors in neuroblastoma hybrid cells; evidence for differences in the mechanisms of action of sodium butyrate and naltrexone. J. Pharmacol. Exp. Ther. 259:1991;302-309.
7. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 43:1988;72-78.
8. Bohn L.M., Belcheva M.M., Coscia C.J. Evidence for κ and μ opioid receptor expression in c6 glioma cells. J. Neurochem. 70:1998;1819-1825.
9. Brodsky M., Elliott K., Hynansky A., Inturrisi C.E. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res. Bull. 38:1995;135-141.
10. Brown E.E., Finlay J.M., Wong J.T.F., Damsma G., Fibiger H.C. Behavioral and neurochemical interactions between cocaine and buprenorphine. Implications for the pharmacotherapy of cocaine abuse. J. Pharmacol. Exp. Ther. 256:1991;119-126.
11. Clark J.A., Myers P.H., Goelz M.F., Thigpen J.E., Forsythe D.B. Pica behavior associated with buprenorphine administration in the rat. Lab. Animal Sci. 47:1997;300-303.
12. Drake C.T., Patterson T.A., Simmons M.L., Chavkin C., Milner T.A. Kappa opioid receptor-like immunoreactivity in guinea pig brain: ultrastructural localization in presynaptic terminals in hippocampal formation. J. Comp. Neurol. 370:1996;377-395.
13. Enters E.K., Guo H., Pandey U., Ko D., Robinson S.E. The effect of prenatal methadone exposure on development and nociception during the early postnatal period of the rat. Neurotoxicol. Teratol. 13:1991;161-166.
14. Garzon J., Juarros J.L., Castro M.A., Sanchez-Blazquez P. Antibodies to the cloned μ-opioid receptor detect various molecular weight forms in areas of mouse brain. Mol. Pharmacol. 47:1995;738-744.
15. Howard A.D., deLa Baume S., Gioannini T.L., Hiller J.M., Simon E.J. Covalent labeling of opioid receptors with radioiodinated human β-endorphin. J. Biol. Chem. 260:1985;10833-10839.
16. Hutchings D.E., Hamowy A.S., Willimiams E.M., Zmitrovich A.C. Prenatal administration of buprenorphine in the rat: effects on the rest-activity cycle at 22 and 30 days of age. Pharmacol. Biochem. Behav. 55:1996;607-613.
17. Hutchings D.E., Feraru E., Gorinson H.S., Golden R. The effects of prenatal exposure to methadone on the rest-activity cycle of the preweanling rat. Neurobehav. Toxicol. Teratol. 1:1979;33-40.
18. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. J. Am. Med. Assoc. 267:1992;2750-2755.
19. Kim D.S., Chin H., Klee W.A. Agonist regulation of the expression of the delta opioid receptor in NG108-15 cells. FEBS Letters. 376:1995;11-14.
20. Kimmel H.L., Tallarida R.J., Holtzman S.G. Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat. Psychopharmacology. 133:1997;372-377.
21. Kosten T.R., Krystal J.H., Charney D.S., Price L.H., Morgan C.H., Kleber H.D. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend. 25:1990;73-78.
22. C.M. Kuhn, R.T. Windh, P.J. Little, Effects of perinatal opiate addiction on neurochemical development of the brain, in: M.W. Miller (Ed.), Development of the Central Nervous System, Wiley-Liss, New York, NY, 1992, pp. 341-361.
23. Law F.D., Bailey J.E., Allen D.S., Melichar J.K., Myles J.S., Mitcheson M.C., Lewis J.W., Nutt D.J. The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. Addiction Biology. 2:1997;191-200.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
25. Marquet P., Chevrel J., Lavignasse P., Merle L., Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin. Pharmacol. Ther. 62:1997;569-571.
26. Mello N.K., Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science. 207:1980;657-659.
27. Mendelson J., Jones R.T., Fernandez I., Welm S., Melby A.K., Baggott M.J. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin. Pharmacol. Ther. 60:1996;105-114.
28. Mori N., Sakanoue M., Kamata S., Takeuchi M., Shimpo K., Tamagawa M. Toxicological studies of buprenorphine: II. Teratogenicity in rat. Iyakuhin Kenkyu. 13:1982;509-531.
29. Mori N., Sakanoue M., Kamata S., Takeuchi M., Shimpo K., Tamagawa M. Buprenorphine: toxicological studies of buprenorphine: III. Perinatal and postnatal study in rat. Iyakuhin Kenkyu. 13:1982;532-544.
30. Munson P.J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
31. Olley J.E., Tiong G.K., Pierce T.L. A study of opiate abuse during pregnancy using a rat model NIDA. Res. Monograph. 119:1992;397.
32. Schottenfeld R.S., Pakes J.R., Kosten T.R. Prognostic factors in buprenorphine- versus methadone-maintained patients. J. Nerv. Ment. Dis. 186:1998;35-43.
33. Sehba F., Duttaroy A., Shah S., Chen B., Carroll J., Yoburn B.C. In vivo homologous regulation of mu-opioid receptor gene expression in the mouse. Eur. J. Pharmacol. 339:1997;33-41.
34. Spain J.W., Roth B.L., Coscia C.J. Differential ontogeny of multiple opioid receptors (μ, δ and κ). J. Neurosci. 5:1985;585-588.
35. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 261:1992;985-993.
36. A. Tempel, Regulation of the opioid system by exogenous drug administration, in: M.W. Miller (Ed.), Development of the Central Nervous System, Wiley-Liss, New York, NY, 1992, pp. 319-339.
37. Tempel A., Crain S.M., Peterson E.R., Simon E.J., Zukin R.S. Antagonist-induced opiate receptor upregulation in cultures of fetal mouse spinal cord-ganglion explants. Dev. Brain Res. 25:1986;287-291.
38. Teoh S.K., Mello N.K., Mendelson J.H., Kuehnle J., Gastfriend D.R., Rhoades E., Sholar W. Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men. J. Clin. Psychopharmacol. 14:1994;15-27.
39. Tiong G.K.L., Olley J.E. Effects of exposure in utero to methadone and buprenorphine on enkephalin levels in the developing rat brain. Neurosci. Lett. 93:1988;101-106.
40. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp.Ther. 274:1995;361-372.
41. Warner E.A., Kosten T.R., OConnor P.G. Pharmacotherapy for opioid and cocaine abuse. Med. Clin. N. Am. 81:1997;909-925.
42. I.S. Zagon, P.J. McLaughlin, P.J., An overview of the neurobehavioral sequelae of perinatal opioid exposure, in: J. Yanai (Ed.), Neurobehavioral Teratology, Elsevier, 1984, pp. 197-235.
43. Zagon I.S., McLaughlin P.J., Thompson C.I. Development of motor activity in young rats following methadone exposure. Pharmacol. Biochem. Behav. 10:1979;743-749.
44. Zhu X.-Z., Chuang D.-M. Comparison of the butyrate effects on neurotransmitter receptors in neurohybrids NG108-15 and NCB-20 cells. Life Sci. 41:1987;1133-1139.